Event Details

Verastem Inc at the 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Tuesday, November 18, 2014  through Friday, November 21, 2014 
Title
Verastem Inc at the 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
Date / Time
November 18, 2014
Description

Title: A first-in-Asian phase I dose escalation study to evaluate the safety and pharmacokinetics of VS-6063 (defactinib), a focal adhesion kinase inhibitor in subjects with non-hematologic malignancies
Abstract #: 296
Poster Board #: 076
Date: Thursday, November 20, 2014
Time: 9:00am GMT
Location: Exhibition Hall

Title: FAK inhibitor VS-6063 (defactinib) targets mesothelioma cancer stem cells which are enriched by standard of care chemotherapy
Abstract #: 302
Poster Board #: 082
Date: Thursday, November 20, 2014
Time: 9:00am GMT
Location: Exhibition Hall

Title: PI3K/mTOR inhibitor VS-5584 targets cancer stem cells and prevents tumor regrowth after chemotherapy in preclinical models of small cell lung cancer
Abstract #: 439
Poster Board #: 011
Date: Friday, November 21, 2014
Time: 9:00am GMT
Location: Exhibition Hall